TRUPCR Europe, a UK-based molecular diagnostics company, signs an agreement with Vela Diagnostics to distribute its Sentosa range of NGS products within the UK and Ireland region.
The Vela Sentosa range of products complements the TRUPCR range of qPCR products for infectious diseases and oncology. This deal allows TRUPCR Europe to promote and sell NGS products alongside its TRUPCR range.
The Sentosa range offers a complete NGS workflow solution for automated library prep, thus significantly reducing hands-on time as well as offering a faster turnaround time compared to manual processing. The system also boasts of features such as sample tracking and having an interpretation software that allows results to be generated quickly and easily.
The range offers oncology and infectious disease panels. It has two flagship products: Oncokey 525 is a pan-cancer test that covers more than 525 cancer-related genes. On the other hand, Virokey SQ Flex genotypes HIV-1, HCV, HBV, and CMV to detect resistance to specific types of antiviral drugs.
The partnership allows labs to access NGS and qPCR solutions while increasing efficiencies in workflow and ultimately enhancing patient care.
Harminder Singh, Director of TRUPCR Europe stated, “It’s great to partner with Vela as it was important for our customers to be able to access an NGS workflow alongside our qPCR kits.”
Dr Andreas Goertz, Managing Director of Vela Europe, stated, “We are delighted to partner with TRUPCR Europe. The UK and Ireland are important regions for us, and we feel TRUPCR Europe has the knowledge, people, and skills to allow the partnership to be successful.”